# 101-PGC-005 for the Treatment of COVID-19

> **NCT05656521** · PHASE2 · UNKNOWN · sponsor: **101 Therapeutics** · enrollment: 62 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** 101-PGC-005
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT05656521
- **Lead sponsor:** 101 Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-31
- **Primary completion:** 2023-04-21
- **Final completion:** 2023-06
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2023-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05656521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05656521, "101-PGC-005 for the Treatment of COVID-19". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05656521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*